Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

NCT01902173 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

27

Enrollment

NIH

Sponsor class

Conditions

Hematopoietic and Lymphoid Cell Neoplasm
Locally Advanced Malignant Solid Neoplasm
Locally Advanced Melanoma
Metastatic Malignant Solid Neoplasm
Metastatic Melanoma
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
Unresectable Malignant Solid Neoplasm
Unresectable Melanoma

Interventions

PROCEDURE: Biopsy
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
DRUG: Dabrafenib Mesylate
PROCEDURE: Magnetic Resonance Imaging
DRUG: Trametinib Dimethyl Sulfoxide
DRUG: Uprosertib

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]
[object Object]